甲磺酸阿帕替尼联合FOLFOX方案治疗晚期结直肠癌患者的效果及对血清肿瘤标志物的影响

Effect of Apatinib Mesylate Combined with FOLFOX Regimen on Patients with Advanced Colorectal Cancer and Its Influence on Serum Tumor Markers

目的:探讨甲磺酸阿帕替尼联合FOLFOX方案治疗晚期结直肠癌(CRC)患者的效果及对血清肿瘤标志物和生长分化因子-15(GDF-15)、血清胰岛素样生长因子结合蛋白7(IGFBP7)水平的影响。方法:将南昌大学第四附属医院与南昌县人民医院2018年1月—2021年1月收治的72例晚期CRC患者作为研究对象,根据不同治疗方案分为对照组(n=36)和观察组(n=36)。对照组给予FOLFOX方案治疗,观察组给予甲磺酸阿帕替尼+FOLFOX方案治疗。观察两组客观缓解率(ORR)、血清肿瘤标志物水平、GDF-15、IGFBP7、生存情况及不良反应发生情况。结果:观察组ORR高于对照组,差异有统计学意义(P<0.05);化疗结束后,观察组GDF-15、IGFBP7、癌胚抗原(CEA)、糖类抗原50(CA50)水平均显著低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异均无统计学意义(P>0.05);随访2年,Kaplan-Meier曲线显示观察组累积生存率高于对照组,差异有统计学意义(P<0.05)。结论:甲磺酸阿帕替尼联合FOLFOX方案可以提升晚期CRC患者的ORR和累积生存率,降低GDF-15、IGFBP7及血清肿瘤标志物水平。

Objective:To explore the effect of Apatinib Mesylate combined with FOLFOX regimen on patients with advanced colorectal cancer(CRC)and its influence on serum tumor markers,growth differentiation factor-15(GDF-15)and serum insulin-like growth factor binding protein 7(IGFBP7)levels.Method:A total of 72 patients with advanced CRC admitted to the Fourth Affiliated Hospital of Nanchang University and Nanchang County People's Hospital from January 2018 to January 2021 were selected as the study objects,and divided into control group(n=36)and observation group(n=36)according to different treatment regimen.The control group was given FOLFOX regimen,and the observation group was given Apatinib Mesylate+FOLFOX regimen.Objective response rate(ORR),serum tumor markers levels,GDF-15,IGFBP7,survival situation and adverse reactions of the two groups were observed.Result:The ORR of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,the levels of GDF-15,IGFBP7,carcinoembryonic antigen(CEA)and carbohydrate antigen 50(CA50)in observation group were significantly lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).After 2 years of follow-up,Kaplan-Meier curve showed that the cumulative survival rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion:Apatinib Mesylate combined with FOLFOX regimen can improve the ORR and cumulative survival rate of patients with advanced CRC,and reduce the levels of GDF-15,IGFBP7 and serum tumor markers.